Brokerages Anticipate ZIOPHARM Oncology Inc. (ZIOP) Will Post Quarterly Sales of $1.59 Million

Wall Street brokerages predict that ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) will post sales of $1.59 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for ZIOPHARM Oncology’s earnings, with the highest sales estimate coming in at $1.70 million and the lowest estimate coming in at $1.46 million. ZIOPHARM Oncology posted sales of $1.60 million during the same quarter last year, which would indicate a negative year over year growth rate of 0.6%. The business is scheduled to announce its next quarterly earnings report on Thursday, February 15th.

According to Zacks, analysts expect that ZIOPHARM Oncology will report full-year sales of $1.59 million for the current year, with estimates ranging from $6.26 million to $7.00 million. For the next year, analysts expect that the firm will report sales of $5.41 million per share, with estimates ranging from $3.00 million to $6.40 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover ZIOPHARM Oncology.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. During the same period in the previous year, the firm earned ($0.11) EPS. The business’s revenue was up .0% on a year-over-year basis.

ZIOP has been the subject of several research analyst reports. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, August 28th. HC Wainwright reaffirmed a “buy” rating and issued a $9.50 price objective on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Friday, November 10th. Finally, Raymond James Financial reissued a “hold” rating on shares of ZIOPHARM Oncology in a report on Monday, December 11th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $12.75.

In related news, CEO Laurence James Neil Cooper purchased 6,440 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was acquired at an average price of $4.68 per share, with a total value of $30,139.20. Following the completion of the acquisition, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.40% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Chevy Chase Trust Holdings Inc. purchased a new position in shares of ZIOPHARM Oncology in the third quarter valued at about $104,000. Amalgamated Bank lifted its position in shares of ZIOPHARM Oncology by 12.9% in the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 1,924 shares in the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of ZIOPHARM Oncology by 50.0% in the second quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 6,000 shares in the last quarter. BB&T Securities LLC purchased a new position in shares of ZIOPHARM Oncology in the second quarter valued at about $112,000. Finally, Adell Harriman & Carpenter Inc. purchased a new position in shares of ZIOPHARM Oncology in the third quarter valued at about $141,000. 40.23% of the stock is owned by institutional investors and hedge funds.

Shares of ZIOPHARM Oncology (NASDAQ ZIOP) opened at $4.16 on Friday. ZIOPHARM Oncology has a fifty-two week low of $3.90 and a fifty-two week high of $7.88.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/22/brokerages-anticipate-ziopharm-oncology-inc-ziop-will-post-quarterly-sales-of-1-59-million.html.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit